(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo
F. Gasparini et al., (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo, J PHARM EXP, 289(3), 1999, pp. 1678-1687
Citations number
41
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Group III metabotropic glutamate receptors (mGluRs) are thought to modulate
neurotoxicity of excitatory amino acids, via mechanisms of presynaptic inh
ibition, such as regulation of neurotransmitter release. Here, we describe
(R,S)-4-phosphonophenylglycine (PPG) as a novel, potent, and selective agon
ist for group III mGluRs. In recombinant cell lines expressing the human re
ceptors hmGluR4a, hmGluR6, hmGluR7b, or hmGluR8a, EC50 values for (R,S)-PPG
of 5.2 +/- 0.7 mu M, 4.7 +/- 0.9 mu M, 185 +/- 42 mu M, and 0.2 +/- 0.1 mu
M, respectively, were measured. The compound showed EC50 and IC50 values o
f greater than or equal to 200 mu M at group I and II hmGluRs and was inact
ive at cloned human N-methyl-D-aspartate, alpha-amino-3-hydroxy-5-methyliso
xazole-4-propionate, and kainate receptors (>300 mu M). On the other hand,
it showed micromolar affinity for a Ca2+/Cl--dependent L-glutamate binding
site in rat brain, similar to other phosphono-substituted amino acids like
L-2-amino-4-phosphonobutyrate. In cultured cortical neurons, (R,S)-PPG prov
ided protection against a toxic pulse of N-methyl-D-aspartate (EC50 = 12 mu
M), which was reversed by the group III mGluR antagonist (R,S)-alpha-methy
lserine-O-phosphate but not by the group II antagonist (2S)-alpha-ethylglut
amate. Moreover, (R,S)-PPG protected against N-methyl-D-aspariate- and quin
olinic acid-induced striatal lesions in rats and was anticonvulsive in the
maximal electroshock model in mice. In contrast to the group III mGluR agon
ists L-2-amino-4-phosphonobutyrate and L-serine-O-phosphate, (R,S)-PPG show
ed no proconvulsive effects (2200 nmol i.c.v.). These data provide novel in
vivo evidence for group III mGluRs as attractive targets for neuroprotecti
ve and anticonvulsive therapy. Also, (R,S)-PPG represents an attractive too
l to analyze the roles of group III mGluRs in nervous system physiology and
pathology.